Pulmatrix, Inc. (PULM): R&D Expense
$38.0K
Year ended 2025-12-31
$10.0K
Trailing 12 months to 2026-06-30
-87.2%
3-year compound annual growth
-70.0%
5-year compound annual growth
-40.8%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $38.0K | -99.5% | 2026-06-16, From 2025-01-01 |
| 2024-12-31 | $7.17M | -53.8% | 2026-06-16, From 2024-01-01 |
| 2023-12-31 | $15.52M | -14.9% | 2025-03-21, From 2023-01-01 |
| 2022-12-31 | $18.24M | +18.6% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $15.38M | -1.5% | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | $15.61M | +21.5% | 2022-03-29, From 2020-01-01 |
| 2019-12-31 | $12.85M | -0.9% | 2021-03-23, From 2019-01-01 |
| 2018-12-31 | $12.97M | +26.6% | 2020-03-26, From 2018-01-01 |
| 2017-12-31 | $10.24M | +0.9% | 2019-02-19, From 2017-01-01 |
| 2016-12-31 | $10.15M | +41.3% | 2018-03-13, From 2016-01-01 |
| 2015-12-31 | $7.19M | +9.1% | 2017-03-10, From 2015-01-01 |
| 2014-12-31 | $6.59M | n/a | 2016-03-10, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | 2025-12-31 | $38.0K | -99.5% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $8.24M | +249.0% |
| Cadrenal Therapeutics, Inc. (CVKD) | 2025-12-31 | $4.10M | -2.5% |
| Bio-Path Holdings, Inc. (BPTH) | 2024-12-31 | $7.29M | -37.2% |
| Protagenic Therapeutics, Inc.\new (PTIX) | 2026-03-31 | $901.9K | +139.4% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $684.0K | +4.1% |
| Azitra, Inc. (AZTR) | 2025-12-31 | $4.84M | +2.4% |
| Enveric Biosciences, Inc. (ENVB) | 2025-12-31 | $2.78M | -2.1% |
| Petros Pharmaceuticals, Inc. (PTPI) | 2024-12-31 | $2.62M | +8.5% |
Compare PULM, LEXX, CVKD, BPTH side by side · Screen every company in Pharmaceutical Preparations ↗